ClinicalTrials.gg
Not yet recruitingNCT07943000TRACerUpdated Nov 17, 2026

Phase 0 Study to Define the Effect of Low Dose Ethacrynic Acid on Total Glutathione (GSH) Levels and Glutathione S-transferase (GST) Activity

An Early Phase 1 interventional study of ethacrynic acid in Healthy Volunteers and Redox Biology, sponsored by University of Vermont Medical Center. Not yet recruiting. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Vermont Medical Center · Early Phase 1, Interventional, and Basic science

How we know

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will examine how low doses of ethacrynic acid affect substances in the blood involved in protecting cells from damage. These substances include glutathione and an enzyme called glutathione S-transferase. The findings may help researchers plan future cancer studies.

Ethacrynic acid is an approved prescription medicine used to treat fluid buildup. Its use in this study to change these blood markers in healthy adults is experimental.

Up to 40 healthy adults will participate. The first group will receive a 25 mg oral dose at each of two visits approximately one week apart. If results meet the study criteria, a second group will receive 12.5 mg at each visit.

Participants will provide blood samples before and approximately 90 minutes after each dose. Study staff will ask about symptoms during the visits and during a final telephone call approximately one week after the second dose. Participation will last approximately two weeks.

Read the detailed description

Glutathione (GSH) and glutathione S-transferases (GSTs) contribute to cellular protection against oxidative stress and the detoxification of electrophilic compounds. In cancer cells, increased activity of these systems may contribute to resistance to anticancer therapies. Ethacrynic acid, an approved loop diuretic, can inhibit GST activity and react with GSH to form conjugates, potentially reducing cellular GSH availability. Whether low oral doses produce measurable pharmacodynamic effects in healthy adults remains uncertain.

TRACer will investigate these biological effects in healthy volunteers to reduce confounding from malignancy, prior cancer treatment, organ dysfunction, and concurrent prescription medications. The study uses paired measurements before and after drug administration, allowing each participant to serve as their own control. Repeating administration approximately one week later will help characterize the consistency of the pharmacodynamic response. Comparison of pre-dose measurements across visits will also provide information about whether changes persist between administrations.

The sequential cohort design evaluates the higher dose first. Enrollment into the lower-dose cohort will occur only if the initial cohort meets the protocol-specified criterion for biological activity. This approach is intended to determine whether target engagement can be demonstrated at doses below those commonly used to produce diuresis.

Peripheral blood mononuclear cells provide accessible material for assessing GST activity. Measurements of total GSH in plasma and erythrocytes provide complementary information about glutathione pools in different blood compartments. Coded specimens will undergo research laboratory analysis at the University of Vermont. These assays will not guide clinical care, and individual research results will not be returned to participants.

The study is intended to inform the design of subsequent investigations of ethacrynic acid as a potential adjunct to cancer therapy. It does not evaluate antitumor activity, and no direct clinical benefit to participants is anticipated.

02

Conditions studied

  • Healthy Volunteers
  • Redox Biology

Keywords

  • Ethacrynic Acid
  • Pharmacodynamics
  • Glutathione S-Transferase
  • Glutathione
  • Redox Biology
03

In context

Lead sponsor

University of Vermont Medical Center is the lead sponsor of 44 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy volunteer without acute or chronic illness.
  • Age 18 years or older.
  • Willing and able to provide .

Exclusion criteria

Exclusion Criteria:

  • Ongoing use of any prescription medication.
  • Known to ethacrynic acid.
  • Known renal or hepatic impairment.
  • Current pregnancy or breastfeeding.
  • Current tinnitus, hearing impairment, or other significant hearing disorder.
  • Baseline systolic blood pressure of 100 mm Hg or less.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Early Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Ethacrynic Acid 25 mg

    Approximately 20 participants will receive ethacrynic acid 25 mg orally at each of two dosing visits separated by one week ±1 day.

    Drug: ethacrynic acid

  • Experimental
    Ethacrynic Acid 12.5 mg

    If the first cohort meets the protocol-specified biological activity criterion, approximately 20 additional participants will receive ethacrynic acid 12.5 mg orally at each of two dosing visits separated by one week ±1 day.

    Drug: ethacrynic acid

Interventions

  • Oral ethacrynic acid administered at 25 mg or 12.5 mg per dose, according to cohort, on two occasions approximately one week apart.

    Also known as: Edecrin

06

What researchers measure

Primary outcomes

  1. Change in Peripheral Blood Mononuclear Cell GST Activity

    Change in glutathione S-transferase activity from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

    Time frame: Before dosing and 90 ±15 minutes after dosing at the first visit and the second visit approximately one week later

Secondary outcomes

  1. Change in Plasma Total Glutathione

    Change in plasma total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

    Time frame: Before dosing and 90 ±15 minutes after dosing at both dosing visits

  2. Change in Erythrocyte Total Glutathione

    Change in erythrocyte total glutathione from the pre-dose measurement to the post-dose measurement, evaluated separately for each dosing visit.

    Time frame: Before dosing and 90 ±15 minutes after dosing at both dosing visits

  3. Number of Participants With Adverse Events

    Number of participants experiencing adverse events, summarized by event type, severity, and relatedness. Severity will be graded using the protocol's CTCAE criteria.

    Time frame: From the first dosing visit through the final telephone assessment, one week ±2 days after the second dosing visit, approximately two weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2029; primary completion for Jan 2029, 0 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Jan 2029
Primary completionEst.
Jan 2029
CompletionEst.
Jan 2029
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07943000
Lead sponsor
University of Vermont Medical Center
Responsible party
Randall F Holcombe (Director-Faculty, University of Vermont Medical Center) — Principal investigator
First posted
Nov 17, 2026
Start date
Jan 2029 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Jan 2029 (estimated)
Last update
Nov 17, 2026

Study contacts

Randall Holcombe, MD, MBA
Contact
Randall.holcombe@med.uvm.edu
802-656-2207

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethacrynic Acid

Start the discussion